Kathrin Zürcher1, Anne Mooser1, Nanina Anderegg1, Olga Tymejczyk2,3, Margaret J Couvillon1, Denis Nash2,3, Matthias Egger1,4. 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2. Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, City University of New York School of Public Health, New York, NY, USA. 4. Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVE: The retention of patients on antiretroviral therapy (ART) is key to achieving global targets in response to the HIV epidemic. Loss to follow-up (LTFU) can be substantial, with unknown outcomes for patients lost to ART programmes. We examined changes in outcomes of patients LTFU over calendar time, assessed associations with other study and programme characteristics and investigated the relative success of different tracing methods. METHODS: We performed a systematic review and logistic random-effects meta-regression analysis of studies that traced adults or children who started ART and were LTFU in sub-Saharan African treatment programmes. The primary outcome was mortality, and secondary outcomes were undocumented transfer to another programme, treatment interruption and the success of tracing attempts. RESULTS: We included 32 eligible studies from 12 countries in sub-Saharan Africa: 20 365 patients LTFU were traced, and 15 708 patients (77.1%) were found. Compared to telephone calls, tracing that included home visits increased the probability of success: the adjusted odds ratio (aOR) was 9.35 (95% confidence interval [CI] 1.85-47.31). The risk of death declined over calendar time (aOR per 1-year increase 0.86, 95% CI 0.78-0.95), whereas undocumented transfers (aOR 1.13, 95% CI 0.96-1.34) and treatment interruptions (aOR 1.31, 95% CI 1.18-1.45) tended to increase. Mortality was lower in urban than in rural areas (aOR 0.59, 95% CI 0.36-0.98), but there was no difference in mortality between adults and children. The CD4 cell count at the start of ART increased over time. CONCLUSIONS: Mortality among HIV-positive patients who started ART in sub-Saharan Africa, were lost to programmes and were successfully traced has declined substantially during the scale-up of ART, probably driven by less severe immunodeficiency at the start of therapy.
OBJECTIVE: The retention of patients on antiretroviral therapy (ART) is key to achieving global targets in response to the HIV epidemic. Loss to follow-up (LTFU) can be substantial, with unknown outcomes for patients lost to ART programmes. We examined changes in outcomes of patients LTFU over calendar time, assessed associations with other study and programme characteristics and investigated the relative success of different tracing methods. METHODS: We performed a systematic review and logistic random-effects meta-regression analysis of studies that traced adults or children who started ART and were LTFU in sub-Saharan African treatment programmes. The primary outcome was mortality, and secondary outcomes were undocumented transfer to another programme, treatment interruption and the success of tracing attempts. RESULTS: We included 32 eligible studies from 12 countries in sub-Saharan Africa: 20 365 patients LTFU were traced, and 15 708 patients (77.1%) were found. Compared to telephone calls, tracing that included home visits increased the probability of success: the adjusted odds ratio (aOR) was 9.35 (95% confidence interval [CI] 1.85-47.31). The risk of death declined over calendar time (aOR per 1-year increase 0.86, 95% CI 0.78-0.95), whereas undocumented transfers (aOR 1.13, 95% CI 0.96-1.34) and treatment interruptions (aOR 1.31, 95% CI 1.18-1.45) tended to increase. Mortality was lower in urban than in rural areas (aOR 0.59, 95% CI 0.36-0.98), but there was no difference in mortality between adults and children. The CD4 cell count at the start of ART increased over time. CONCLUSIONS: Mortality among HIV-positivepatients who started ART in sub-Saharan Africa, were lost to programmes and were successfully traced has declined substantially during the scale-up of ART, probably driven by less severe immunodeficiency at the start of therapy.
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Rishikesh P Dalal; Catherine Macphail; Mmabatho Mqhayi; Jeff Wing; Charles Feldman; Matthew F Chersich; Willem D F Venter Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Matthias Egger; Ben D Spycher; John Sidle; Ralf Weigel; Elvin H Geng; Matthew P Fox; Patrick MacPhail; Gilles van Cutsem; Eugène Messou; Robin Wood; Denis Nash; Margaret Pascoe; Diana Dickinson; Jean-François Etard; James A McIntyre; Martin W G Brinkhof Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Rimke Bijker; Sasisopin Kiertiburanakul; Nagalingeswaran Kumarasamy; Sanjay Pujari; Ly P Sun; Oon T Ng; Man P Lee; Jun Y Choi; Kinh V Nguyen; Yu J Chan; Tuti P Merati; Do D Cuong; Jeremy Ross; Awachana Jiamsakul Journal: Antivir Ther Date: 2020
Authors: Chris T Longenecker; Stephen R Morris; Twalib O Aliku; Andrea Beaton; Marco A Costa; Moses R Kamya; Cissy Kityo; Peter Lwabi; Grace Mirembe; Dorah Nampijja; Joselyn Rwebembera; Craig Sable; Robert A Salata; Amy Scheel; Daniel I Simon; Isaac Ssinabulya; Emmy Okello Journal: Circ Cardiovasc Qual Outcomes Date: 2017-11
Authors: Angela M Bengtson; Wiza Kumwenda; Mark Lurie; Brandon Klyn; Michael Owino; William C Miller; Vivian Go; Mina C Hosseinipour Journal: AIDS Behav Date: 2020-02
Authors: Nanina Anderegg; Jonas Hector; Laura F Jefferys; Juan Burgos-Soto; Michael A Hobbins; Jochen Ehmer; Lukas Meier; Marloes H Maathuis; Matthias Egger Journal: J Clin Epidemiol Date: 2020-08-20 Impact factor: 6.437
Authors: Nanina Anderegg; Leigh F Johnson; Elizabeth Zaniewski; Keri N Althoff; Eric Balestre; Matthew Law; Denis Nash; Bryan E Shepherd; Constantin T Yiannoutsos; Matthias Egger Journal: AIDS Date: 2017-04 Impact factor: 4.177
Authors: A Jiamsakul; S Kiertiburanakul; O T Ng; R Chaiwarith; W Wong; R Ditangco; K V Nguyen; A Avihingsanon; S Pujari; C D Do; M-P Lee; P S Ly; E Yunihastuti; N Kumarasamy; A Kamarulzaman; J Tanuma; F Zhang; J Y Choi; P Kantipong; Blh Sim; J Ross; M Law; T P Merati Journal: HIV Med Date: 2019-04-12 Impact factor: 3.180
Authors: Marie Ballif; Benedikt Christ; Nanina Anderegg; Frédérique Chammartin; Josephine Muhairwe; Laura Jefferys; Jonas Hector; Janneke van Dijk; Michael J Vinikoor; Monique van Lettow; Cleophas Chimbetete; Sam J Phiri; Dorina Onoya; Matthew P Fox; Matthias Egger Journal: Clin Infect Dis Date: 2022-01-29 Impact factor: 9.079
Authors: Olga Tymejczyk; Quynh Vo; Sarah Gorrell Kulkarni; Gretchen Antelman; Judith Boshe; William Reidy; Angela Parcesepe; Denis Nash; Batya Elul Journal: AIDS Care Date: 2019-12-11